Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Receivables (2019 - 2025)

Historic Receivables for BioNexus Gene Lab (BGLC) over the last 7 years, with Q3 2025 value amounting to $1.6 million.

  • BioNexus Gene Lab's Receivables rose 872.12% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 872.12%. This contributed to the annual value of $1.6 million for FY2024, which is 7137.19% up from last year.
  • Per BioNexus Gene Lab's latest filing, its Receivables stood at $1.6 million for Q3 2025, which was up 872.12% from $2.0 million recorded in Q2 2025.
  • Over the past 5 years, BioNexus Gene Lab's Receivables peaked at $4.2 million during Q3 2021, and registered a low of $922106.0 during Q4 2023.
  • Over the past 5 years, BioNexus Gene Lab's median Receivables value was $2.2 million (recorded in 2023), while the average stood at $2.3 million.
  • As far as peak fluctuations go, BioNexus Gene Lab's Receivables crashed by 6813.3% in 2023, and later skyrocketed by 7739.17% in 2025.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Receivables stood at $3.4 million in 2021, then dropped by 15.8% to $2.9 million in 2022, then tumbled by 68.13% to $922106.0 in 2023, then surged by 71.37% to $1.6 million in 2024, then grew by 2.58% to $1.6 million in 2025.
  • Its Receivables was $1.6 million in Q3 2025, compared to $2.0 million in Q2 2025 and $1.7 million in Q1 2025.